Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1636582 | 0.92 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL7936511 | 0.92 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL3685793 | 0.92 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL13336904 | 0.92 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL1636580 | 0.92 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL13336902 | 0.89 | ADORA3 (0.41) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL8107691 | 0.88 | NAMPT (0.31) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL8107461 | 0.87 | NAMPT (0.32) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL12726025 | 0.87 | ADORA3 (0.39) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL12765158 | 0.87 | ELANE (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008141227-A1 | NOVEL PEPTIDE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2008-11-20 | — | — | WO | disclosed |